Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience

INTRODUCTION: Bevacizumab plus carboplatin-paclitaxel (BCP) chemotherapy has FDA approval for advanced non-squamous, non-small cell lung cancer (NS-NSCLC) based upon improved survival in a clinical trial. However, sub-group analyses of this and other studies have suggested variable results by age an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Thorac Oncol
Hlavní autoři: Ritzwoller, Debra P., Carroll, Nikki M., Delate, Thomas, Hornbrook, Mark C., Kushi, Lawrence, Aiello Bowles, Erin J., Loggers, Elizabeth T., Menter, Alex
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5083067/
https://ncbi.nlm.nih.gov/pubmed/24633407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000127
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky